Stryker To Pay $15M To End False Marketing Case
The company submitted a change of plea agreement altering its not-guilty plea to guilty after the government filed a superseding indictment in the case changing its charges against the company. Stryker now pleads guilty to one misdemeanor count of misbranding a medical device.
“Stryker Biotech expressly and unequivocally admits that it committed the misdemeanor...
To view the full article, register now.